Evidence map›Paper›PMID 37679715›Full record

ArticleBMC cancer2023

Systematic analysis of RNASET2 gene as a potential prognostic and immunological biomarker in clear cell renal cell carcinoma.

Yifu Liu, Zhicheng Zhang, Ping Xi, Ru Chen, Xiaofeng Cheng, Ji Liu, Qiqi Zhu, Yechen Nie, Ting Sun, Binbin Gong and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yifu Liu *Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Zhicheng Zhang *Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Ping Xi *Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Ru ChenDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Xiaofeng ChengDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Ji LiuDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Qiqi ZhuDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Yechen NieDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Ting SunDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China. 361439919033@email.ncu.edu.cn.
Binbin GongDepartment of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China. 15270993912@163.com.
Siyuan WangDepartment of Urology, Sichuan Cancer Hospital School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, 610041, Sichuan, China. 876844845@qq.com.
First Affiliated Hospital of Nanchang University · CNNanchang University · CNUniversity of Electronic Science and Technology of China · CN

Funding

the Project of Science and Technology Plan of Jiangxi Provincial Health and Health Commission in 2021 202130209the Science and Technology Foundation of Jiangxi Provincial Education Department GJJ210132
6 · The paper itself

Abstract

backgroundRNASET2 has been identified as an oncogene with anti-angiogenic and immunomodulatory effects in a variety of cancers, but its function in clear cell renal cell carcinoma (ccRCC) is still not well understood.

methodsThe RNASET2 expression matrix was extracted from the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets and analyzed for diagnostic and prognostic value. RNASET2 mRNA expression was detected by quantitative polymerase chain reaction (qPCR) in ccRCC patients and renal cancer cell lines. Wound healing assay, transwell assay, western blotting, and tube formation assays were used to evaluate the function of RNASET2 in renal cancer in vitro. In addition, transcriptome sequencing was performed on knockdown RNASET2 kidney cancer cells to analyze their potential signaling pathways. Moreover, the immune microenvironment and mutational status were evaluated to predict the potential mechanisms of RNASET2 involvement in renal cancer progression. Sensitivity to common chemotherapeutic and targeted agents was assessed according to the Genomics of Drug Sensitivity in Cancer (GDSC) database.

resultsRNASET2 expression was significantly upregulated in ccRCC tissues and renal cancer cell lines, predicting poor prognosis for patients. In vitro experiments showed that silencing RNASET2 inhibited the migration and pro-angiogenic ability of renal cancer cells. Transcriptome sequencing suggested its possible involvement in the remodeling of the immune microenvironment in renal cell carcinoma. Furthermore, bioinformatics analysis and immunohistochemical staining showed that RNASET2 was positively correlated with the infiltration abundance of regulatory T cells. Finally, we mapped the mutational landscape of RNASET2 in ccRCC and found its predictive value for drug sensitivity.

conclusionsOur results suggest that RNASET2 is a promising biomarker and therapeutic target in ccRCC.

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsBiomarkersHumansPrognosisRibonucleasesTumor MicroenvironmentTumor Suppressor ProteinsBiomarkersRibonucleasesRNASET2 protein, humanTumor Suppressor ProteinsBiomarkerClear cell renal cell carcinomaPrognosticRNASET2

Identifiers

PMID37679715
PMCPMC10483861
OpenAlexW4386511262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.